NYSE · PTHS
Healthcare · Biotechnology
$24.35
Down-$0.01 (-0.04%)
Updated Sep 6, 2026, 9:51 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PTHS closed at $24.35 after 20 trading sessions, down 16.03% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $24.44 | $24.79 | $24.01 | $24.35 | 18.8K |
| Sep 3, 2026 | $25.18 | $25.60 | $24.06 | $24.36 | 43.48K |
| Sep 2, 2026 | $24.59 | $26.10 | $23.26 | $25.03 | 87.88K |
| Sep 1, 2026 | $23.90 | $24.825 | $23.71 | $24.82 | 18.86K |
| Aug 31, 2026 | $24.16 | $25.9151 | $23.27 | $24.08 | 79.24K |
| Aug 28, 2026 | $24.605 | $25.835 | $24.00 | $24.73 | 40.91K |
| Aug 27, 2026 | $26.48 | $27.08 | $24.51 | $25.00 | 83.49K |
| Aug 26, 2026 | $27.07 | $27.50 | $26.31 | $26.78 | 36.43K |
| Aug 25, 2026 | $27.09 | $28.1703 | $25.97 | $27.20 | 50.93K |
| Aug 24, 2026 | $25.52 | $27.23 | $24.65 | $26.62 | 151.27K |
| Aug 21, 2026 | $26.41 | $28.4731 | $25.00 | $25.51 | 21.64K |
| Aug 20, 2026 | $26.03 | $27.315 | $25.86 | $26.66 | 24.24K |
| Aug 19, 2026 | $26.59 | $28.135 | $25.74 | $25.82 | 17.79K |
| Aug 18, 2026 | $25.69 | $27.46 | $25.69 | $26.11 | 21.17K |
| Aug 17, 2026 | $27.23 | $28.055 | $25.84 | $25.90 | 29.26K |
| Aug 14, 2026 | $28.00 | $28.63 | $26.97 | $27.50 | 23.29K |
| Aug 13, 2026 | $27.80 | $29.80 | $25.83 | $28.95 | 44.12K |
| Aug 12, 2026 | $28.84 | $29.02 | $28.02 | $28.91 | 23.51K |
| Aug 11, 2026 | $28.88 | $29.08 | $28.30 | $28.63 | 37.82K |
| Aug 10, 2026 | $28.20 | $29.00 | $28.20 | $29.00 | 21.44K |
The latest Smart Investors Daily articles mentioning PTHS.
PTHS research
Company profile and research snapshot.
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Outperform | — |
| May 15, 2026 | Oppenheimer | Outperform | — |
| Apr 1, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 20, 2026 | Oppenheimer | Outperform | — |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 27, 2026
Piper Sandler analyst David Amsellem initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Overweight rating and announces Price Target of $48.
Benzinga · Feb 26, 2026
Roth Capital analyst Jonathan Aschoff maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $57 to $55.
Yahoo · Feb 23, 2026
DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time. The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during
Benzinga · Feb 2, 2026
SEC.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PTHS.
